Archive for Journal


Product Description
This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on November 4, 2002. The length of the article is 438 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Amylin watches its R&D costs continue to rise. (Biotech).(Amylin Pharmaceuticals research and development spending)
Author: Marion Webb
Publication: San Diego Business Journal (Magazine/Journal)
Date: November 4, 2002
Publisher: CBJ, L.P.
Volume: 23 Issue: 44 Page: 13(1)

Distributed by Thomson Gale
Amylin watches its R&D costs continue to rise. : An article from: San Diego Business Journal

Categories : Trials
Comments (1)


Product Description
This digital document is an article from Nephrology Nursing Journal, published by Jannetti Publications, Inc. on May 1, 2005. The length of the article is 790 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Discussion of patient recruitment and the informed consent process in clinical drug trials.(Professional Issues)
Author: Jerolee White
Publication: Nephrology Nursing Journal (Magazine/Journal)
Date: May 1, 2005
Publisher: Jannetti Publications, Inc.
Volume: 32 Issue: 3 Page: 354(1)

Distributed by Thomson Gale
Discussion of patient recruitment and the informed consent process in clinical drug trials.: An article from: Nephrology Nursing Journal

Categories : Trials
Comments (0)


Product Description
This digital document is an article from Journal of Neuroscience Nursing, published by American Association of Neuroscience Nurses on April 1, 2003. The length of the article is 5552 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Longitudinal analysis of illness uncertainty, coping, hopefulness, and mood during participation in a clinical drug trial.(neuroscience nursing research; includes statistical tables)
Author: N. Margaret Wineman
Publication: Journal of Neuroscience Nursing (Refereed)
Date: April 1, 2003
Publisher: American Association of Neuroscience Nurses
Volume: 35 Issue: 2 Page: 100(7)

Distributed by Thomson Gale
Longitudinal analysis of illness uncertainty, coping, hopefulness, and mood during participation in a clinical drug trial.(neuroscience nursing research; … from: Journal of Neuroscience Nursing

Categories : Trials
Comments (0)


Product Description
This digital document is an article from San Diego Business Journal, published by CBJ, L.P. on November 4, 2002. The length of the article is 438 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Amylin watches its R&D costs continue to rise. (Biotech).(Amylin Pharmaceuticals research and development spending)
Author: Marion Webb
Publication: San Diego Business Journal (Magazine/Journal)
Date: November 4, 2002
Publisher: CBJ, L.P.
Volume: 23 Issue: 44 Page: 13(1)

Distributed by Thomson Gale
Amylin watches its R&D costs continue to rise. : An article from: San Diego Business Journal

Categories : Trials
Comments (0)


Product Description
This digital document is an article from Defense Counsel Journal, published by Thomson Gale on January 1, 2006. The length of the article is 6591 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: The learned intermediary doctrine after FDA’s drug watch and PhRMA’s clinical study results database: shifting the focus of failure-to-warn claims.(Pharmaceutical Researchers and Manufacturers Association)
Author: Stephen E. Scheve
Publication: Defense Counsel Journal (Magazine/Journal)
Date: January 1, 2006
Publisher: Thomson Gale
Volume: 73 Issue: 1 Page: 12(10)

Distributed by Thomson Gale
The learned intermediary doctrine after FDA’s drug watch and PhRMA’s clinical study results database: shifting the focus of failure-to-warn claims.(Pharmaceutical … An article from: Defense Counsel Journal

Categories : Trials
Comments (0)


Product Description
This digital document is an article from Journal of Studies on Alcohol and Drugs, published by Thomson Gale on May 1, 2007. The length of the article is 10945 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

From the author: Objective: The potential effectiveness of two group-administered social-skills training interventions for reducing high-risk drinking behavior was evaluated through a prospective randomized intervention trial with 3,406 members of a national college fraternity. Method: Ninety eight of 99 chapters of a national fraternity were randomly assigned, within three strata, to receive (1) a 3-hour baseline intervention, (2) the same baseline intervention plus two booster sessions, or (3) assessments only. The current article emphasizes a rigorous intent-to-treat analysis model that compares outcomes among members assigned to receive study interventions (vs assessment-only sites) regardless of whether they actually did receive them; it also includes individuals at intervention sites even if they did not participate. This model allows us to address a social policy issue regarding the effect that introducing such an intervention may have in changing the high-risk normative drinking environment of the fraternity itself. Results: Frequent heavy drinkers (64.2% of members) assigned to either intervention showed significant reductions at a 6-month follow-up in their frequency of drinking, heavy drinking, and drinking to intoxication; plus, they reported consuming fewer drinks overall. At 12 and 18 months postbaseline, these positive outcomes had largely dissipated. Additionally, there was an increase in drinking among lower-risk members 18 months postbaseline, which may be the result of factors other than differential attrition. Conclusions: Findings suggest that introducing such a brief intervention can effectively reduce risky drinking behavior on a short-term basis in high-risk members of a national fraternity. Future studies may wish to focus on strategies for sustaining positive outcomes for longer, plus would benefit, in general, from learning more about mechanisms of change. (J. Stud. Alcohol Drugs 68: 399-409, 2007)

Citation Details
Title: Alcohol risk-reduction skills training in a national fraternity: a randomized intervention trial with longitudinal intent-to-treat analysis *.(Report)
Author: Barry D. Caudill
Publication: Journal of Studies on Alcohol and Drugs (Magazine/Journal)
Date: May 1, 2007
Publisher: Thomson Gale
Volume: 68 Issue: 3 Page: 399(11)

Article Type: Report

Distributed by Thomson Gale
Alcohol risk-reduction skills training in a national fraternity: a randomized intervention trial with longitudinal intent-to-treat analysis *.: … Journal of Studies on Alcohol and Drugs

Categories : Trials
Comments (0)


Product Description
This digital document is an article from San Diego Business Journal, published by Thomson Gale on June 20, 2005. The length of the article is 691 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Somaxon makes big entry into competitive arena: insomnia drug will push Neurocrine for $2.5 billion market.(Biotech)(Somaxon Pharmaceuticals Inc. tests Silenor)
Author: Marion Webb
Publication: San Diego Business Journal (Magazine/Journal)
Date: June 20, 2005
Publisher: Thomson Gale
Volume: 26 Issue: 25 Page: 10(1)

Distributed by Thomson Gale
Somaxon makes big entry into competitive arena: insomnia drug will push Neurocrine for $2.5 billion market.(Somaxon Pharmaceuticals Inc. tests … An article from: San Diego Business Journal

Categories : Trials
Comments (0)


Product Description
This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on April 1, 2006. The length of the article is 1403 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Alefacept in the treatment of psoriatic nail disease: a proof of concept study.
Author: Charles A. Parrish
Publication: Journal of Drugs in Dermatology (Magazine/Journal)
Date: April 1, 2006
Publisher: Thomson Gale
Volume: 5 Issue: 4 Page: 339(2)

Distributed by Thomson Gale
Alefacept in the treatment of psoriatic nail disease: a proof of concept study.: An article from: Journal of Drugs in Dermatology

Categories : Trials
Comments (0)